Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

What is willingness to pay? – Comparing price testing methodologies

Heather Wellam (Senior Consultant – Market Access, Mtech Access) explores the concept of willingness to pay (WTP) and what it means for pharmaceutical and medtech pricing strategy. Read on to...

Petauri Evidence

- PMLiVE

Ipsen’s Iqirvo receives EC approval to treat primary biliary cholangitis in adults

The rare liver disease affects approximately nine women for every one man

- PMLiVE

Sanofi/Regeneron’s Dupixent recommended by CHMP for younger eosinophilic oesophagitis patients

If approved, Dupixent would be the first drug in the EU indicated for this patient population

- PMLiVE

From lab to life: harnessing real-world evidence for informed clinical insights and improved patient outcomes

By Stephen Deacon

- PMLiVE

Embracing risk: it’s time for big thinking in neurodegeneration

Drug discovery is an inherently risky endeavour, but society relies upon new drug discoveries and innovations

- PMLiVE

J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC

Alterations in EGFR are among the most common driver mutations in lung cancer patients

EU flag

EC approves Bavarian Nordic’s mpox vaccine Imvanex for use in adolescents

More than 120 countries have confirmed over 103,000 cases of mpox since the global outbreak began in 2022

- PMLiVE

Sanofi shares positive late-stage results for investigational BTK inhibitor in progressive MS

Tolebrutinib is currently being evaluated in various forms of the neurological disorder

- PMLiVE

Wedgewood appoints Danielle Cranwell as president and global agency head

Cranwell most recently served as executive vice president, managing partner at Biolumina

- PMLiVE

Seeing giraffes in the boardroom

Why strategy sometimes needs a nudge

- PMLiVE

Novo Nordisk and NanoVation to develop genetic medicines in partnership worth $600m

The companies will collaborate on up to seven programmes for cardiometabolic and rare diseases

- PMLiVE

Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 lung cancer trial

EGFR-activating mutations occur in up to 38% of all NSCLC tumours globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links